A combination vaccine approach utilizing replication competent adenovirus-HIV or SIV-recombinants to prime immune responses followed by boosting with subunit protein elicits humoral, cellular, and mucosal immune responses in non-human primates. Significant protection against infection and/or disease progression has been demonstrated in chimpanzee and macaque models. These results have provided the basis for moving the strategy forward into human phase I trials. The first trials will be conducted using replication competent Ad4-HIV recombinants, as Ad4 wild type vaccines have an extensive safety and efficacy record in people. To further develop our AIDS vaccine approach we have generated a number of new recombinants including Ad4-based recombinants encoding """"""""codon-optimized"""""""" HIV genes for enhanced expression of HIV gene products, and Ad7 recombinants constructed using a new cosmid system. Recombinants based in different Ad serotypes provide a mechanism for sequential immunization that circumvents host immune responses elicited by the immunizing vector itself. The Ad7 cosmid vectors will be useful not only for construction of HIV recombinants but also can be applied more generally as gene therapy vectors. In preclinical vaccine studies we have investigated in greater depth SIV-specific cellular immune responses elicited by the vaccine regimen, using state-of-the-art methods to quantify CD8+ T-cell responses. We have shown that the replication competent Ad-recombinant approach elicits SIV-specific CD8+ T-cell responses in rhesus macaques equivalent to or greater than other vaccine approaches utilizing live recombinant vectors. In vaccine challenge experiments we have shown that the protective efficacy achieved is correlated with the number of IFN-gamma-secreting cells induced in response to SIV peptide epitopes. The rhesus macaque model is critical for preclinical AIDS vaccine studies. Our studies of a rhesus macaque resistant to SIV infection has shown that a host mechanism, leading to a block in the viral replication cycle post-cellular entry is responsible for the resistance observed. This observation should lead to methods of screening the macaque population for innate resistance, thereby improving the animal model by allowing selection of susceptible macaques with a consequent reduction in the viral challenge dose necessary for infecting control subjects. Preclinical challenge experiments may therefore be conducted using doses of challenge virus more comparable to the doses encountered in natural human infection. Further, the finding provides the platform for further studies investigating the underlying biochemical or immunologic mechanism. The outcome will provide insight into human host-resistance mechanisms which may be exploited for therapeutic or prophylactic purposes. AIDS title: Adenovirus-Recombinant/Subunit Protein Vaccines for AIDS.

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC005536-16
Application #
6761556
Study Section
(BRL)
Project Start
Project End
Budget Start
Budget End
Support Year
16
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Mohanram, Venkatramanan; Demberg, Thorsten; Musich, Thomas et al. (2016) B Cell Responses Associated with Vaccine-Induced Delayed SIVmac251 Acquisition in Female Rhesus Macaques. J Immunol 197:2316-24
Tuero, Iskra; Venzon, David; Robert-Guroff, Marjorie (2016) Mucosal and Systemic ??+ T Cells Associated with Control of Simian Immunodeficiency Virus Infection. J Immunol 197:4686-4695
Musich, Thomas; Robert-Guroff, Marjorie (2016) New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design. Expert Rev Vaccines 15:1015-27
Musich, Thomas; Demberg, Thorsten; Morgan, Ian L et al. (2015) Purification and functional characterization of mucosal IgA from vaccinated and SIV-infected rhesus macaques. Clin Immunol 158:127-39
Demberg, Thorsten; Mohanram, Venkatramanan; Musich, Thomas et al. (2015) Loss of marginal zone B-cells in SHIVSF162P4 challenged rhesus macaques despite control of viremia to low or undetectable levels in chronic infection. Virology 484:323-33
Vargas-Inchaustegui, Diego A; Robert-Guroff, Marjorie (2013) Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention. Curr HIV Res 11:407-20
Demberg, Thorsten; Brocca-Cofano, Egidio; Kuate, Seraphin et al. (2013) Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques. Virology 440:210-21
Demberg, Thorsten; Robert-Guroff, Marjorie (2009) Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol 28:20-48
Florese, Ruth H; Demberg, Thorsten; Xiao, Peng et al. (2009) Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 182:3718-27
Florese, Ruth H; Wiseman, Roger W; Venzon, David et al. (2008) Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection. Vaccine 26:3312-21

Showing the most recent 10 out of 40 publications